By The Associated Press
ROADBLOCK REMOVED: Human Genome Sciences drops its opposition to being acquired by longtime partner U.K. drugmaker GlaxoSmithKline, thanks to GSK's higher offer.
NEW DEAL: GSK will pay $3.6 billion - $14.25 per share, up from its original $13 offer - for the U.S. biotechnology company. Boards at both companies have approved the agreement.
THE REASON: Human Genome, based in Rockville, Md., makes Benlysta, the first new drug approved in about 50 years for lupus. It also has two compounds in late-stage testing for diseases affecting hundreds of millions of people: Type 2 diabetes and heart disease.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.